Pharmacokinetics of intraventricularly administered teicoplanin in Staphylococci ventriculitis
Article
- 111 Downloads
- 3 Citations
Abstract
Following craniotomy for a medulloblastoma in the posterior cranial fossa, a 6‐year old girl developed a ventriculitis with coagulase negative staphylococci associated with the use of a ventriculostomy. Treatment with intravenous (iv) and intraventricular (ivt) vancomycin resulted in negative cultures of the cerebrospinal fluid, but had to be stopped because of a severe allergic skin reaction. Teicoplanin was administered iv (240 mg once daily) and ivt (10 mg once daily), resulting in high teicoplanin CSF levels that were used to model the pharmacokinetics of ivt teicoplanin in this patient. No signs of recurrent infection or adverse events occurred. It is concluded that a pharmacokinetic model can be derived from this case that can be used as prior to guide teicoplanin intraventricular therapy in other patients.
Coagulase negative Staphylococcus Intraventricular administration Pharmacokinetics Teicoplanin Therapeutic drug monitoring Vancomycin Ventriculitis
Preview
Unable to display preview. Download preview PDF.
References
- 1.Mayhall CG, Archer NH, Lamb VA, Spadora AC, Baggett JW, Ward JD, Narayan RK. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med 1984;310:553-9.Google Scholar
- 2.Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomyrelated infections – an epidemiological study. Acta Neurochir 1986;83:20-3.Google Scholar
- 3.Öhrström JK, Skou JK, Ejlertsen T, Kosteljanetz. Infected ventriculostomy: bacteriology and treatment. Acta Neurochir 1989;100:67-9.Google Scholar
- 4.Shurtleff DB, Foltz EL, Weeks RD, Loeser J. Therapy of Staphylococcus epidermidis: Infections associated with cerebrospinal fluid shunts. Pediatrics 1974;53:55-62.Google Scholar
- 5.Gerner-Smidt P, Stenager E, Kock-Jensen C. Treatment of ventriculostomy-related infections. Acta Neurochir 1988;91:47-9.Google Scholar
- 6.Bayston R, Hart CA, Barnicoat M. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiat 1987;50:1419-23.Google Scholar
- 7.Stahl JP, Croize J, Wolff M, Garaud JJ, Leclerq P, Vachon F, Micoud M. Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis. J Antimicrob Chemother 1987;20:141-2.Google Scholar
- 8.Fan-Havard P, Nahata MC, Bartowski H, Barson WJ, Kosnik EJ. Pharmacokinetics and CSF concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. Chemotherapy 1990;36:103-8.12. Archer GL, Climo MW. Antimicrobial susceptability of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994;38:2231-7.Google Scholar
- 9.Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 1981;3 (supplement): S230-5.Google Scholar
- 10.Gump DW. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis 1981;3 (supplement): S289-92.Google Scholar
- 11.James HE, Wilson HD, Connor JD, Walsh JW. Intraventricular cerebrospinal fluid antibiotic concentrations in patients with intraventricular infections. Neurosurg 1982;10:50-4.Google Scholar
- 12.Archer GL, Climo MW. Antimicrobial susceptability of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994;38:2231-7.Google Scholar
- 13.Murphy OM, Stewart D, Gray J, Bint AJ. Susceptibility of staphylococci to teicoplanin and vancomycin. J Antimicrob Chemother 1996;38:316-7.Google Scholar
- 14.Wood MJ. The comparitive efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;37:209-22.Google Scholar
- 15.Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin-and teicoplanin-induced histamine release and ‘red man syndrome’. Antimicrob Agents Chemother 1990;34:765-9.Google Scholar
- 16.Proost JH, Meyer DKF. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.Google Scholar
- 17.Venditti M, Micozzi A, Serra P, Buniva G, Palma L, Martino P. Intraventricular administration of teicoplanin in shunt associated ventriculitis caused by methicillin resistant Staphylococcus aureus. J Antimicrob Chemother 1988;21:513-5.Google Scholar
- 18.Cruciani M, Navarra A, Di Perri G, Andreoni M, Chiara Danzi M, Concia E, Bassetti D. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992;15:285-9.Google Scholar
- 19.Maserati R, Cruciani M, Azzini M, Carnevale C, Suter F, Concia E. Teicoplanin in the therapy of staphylococcal neuroshunt infections. Int J Clin Pharm Res 1987;7:207-13.Google Scholar
- 20.Fernández Guerrero ML, de Górgolas M, Fernández Roblas R, María Campos J. Treatment of cerebrospinal fluid shunt infections with teicoplanin. Eur J Clin Microbiol Infect Dis 1994;13:1056-8.Google Scholar
- 21.Losonsky GA, Wolf A, Schwalbe RS, Nataro J, Gibson CB, Lewis EW. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994;19:163-5.Google Scholar
- 22.Hirsch BE, Amodio M, Einzig AI, Halevy R, Soeiro R. Instillation of vancomycin into a cerebrospinal fluid reservoir to clear infection: Pharmacokinetic considerations. J Infect Dis 1991;163:197-200.Google Scholar
- 23.Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995;39:1842-7.Google Scholar
Copyright information
© Kluwer Academic Publishers 2000